Alphatec (ATEC)
NASDAQ:ATEC
Want to see ATEC full AI Analyst Report?
ATEC Stock Chart & Stats
$11.10
$0.31(3.32%)
At close: 4:00 PM EST
$11.10
$0.31(3.32%)
Day’s Range― - ―
52-Week Range$6.82 - $23.29
Previous CloseN/A
Volume519.80K
Average Volume (3M)4.13M
Market Cap
$1.27B
Enterprise Value$1.73B
Total Cash (Recent Filing)$139.91M
Total Debt (Recent Filing)$603.06M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Jul 30, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding153,789,300
10 Day Avg. Volume4,600,791
30 Day Avg. Volume4,128,015
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda-1.36K
Forecast
1Y Price Target
$18.91Price Target Upside70.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.31
Revenue Forecast (FY)$883.68M
Bulls Say, Bears Say
Bulls Say
Portfolio Expansion And Higher-margin OfferingsSecuring exclusive U.S. distribution for a next-generation spinal biologic and expanding implants and biologics offerings can increase the value per procedure and boost higher-margin sales across deformity and fusion procedures.
Regulatory Approval And Product PositioningFDA clearance of the Valence robotic navigation system and its compact, lower-cost design position the company to capture share from larger, more expensive robotic platforms in smaller and cost-conscious operating rooms.
Surgeon Adoption And UtilizationA growing active surgeon base combined with rising utilization among existing users indicates the company can increase procedure volumes substantially without a proportional increase in new surgeon additions, improving revenue leverage.
Bears Say
Execution, Regulatory And Legal RisksCommercial execution challenges, potential partnership setbacks, regulatory hurdles, and intellectual property disputes represent material risks that could impede expansion and profitability targets.
Share Price Volatility And Investor SentimentAbrupt, sharp share price declines that appear disconnected from company guidance have created investor confusion and persistent downside pressure that could weigh on market confidence.
Surgical Growth Deceleration And Procedure MixModeration in surgical revenue growth and a shift toward simpler procedures have reduced implied revenue per surgery, potentially limiting near-term top-line momentum.
Alphatec Holdings News
ATEC FAQ
What was Alphatec’s price range in the past 12 months?
Alphatec lowest stock price was $6.82 and its highest was $23.29 in the past 12 months.
What is Alphatec’s market cap?
Alphatec’s market cap is $1.27B.
When is Alphatec’s upcoming earnings report date?
Alphatec’s upcoming earnings report date is Jul 30, 2026 which is in 68 days.
How were Alphatec’s earnings last quarter?
Alphatec released its earnings results on May 05, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.022.
Is Alphatec overvalued?
According to Wall Street analysts Alphatec’s price is currently Undervalued.
Does Alphatec pay dividends?
Alphatec does not currently pay dividends.
What is Alphatec’s EPS estimate?
Alphatec’s EPS estimate is 0.07.
How many shares outstanding does Alphatec have?
Alphatec has 153,789,300 shares outstanding.
What happened to Alphatec’s price movement after its last earnings report?
Alphatec reported an EPS of $0 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went down -31.672%.
Which hedge fund is a major shareholder of Alphatec?
Currently, no hedge funds are holding shares in ATEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.91 (70.35% Upside)
$18.91 (70.35% Upside)
Blogger Sentiment
Bullish
ATEC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.5%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.73%
12-Months-Change
Fundamentals
Return on Equity
-443.09%
Trailing 12-Months
Asset Growth
1.78%
Trailing 12-Months
Company Description
Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
ATEC Company Deck
ATEC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive operational and financial picture: healthy top-line growth (14% total, 17% surgical), strong surgeon and case adoption (23% and 21%), margin expansion, and substantial adjusted EBITDA improvement (97% YoY). Key near-term execution challenges center on EOS system deliveries and installation timing, mix-driven revenue-per-case pressure, and temporary working-capital investments (inventory/instruments). Management updated EOS near-term expectations but maintained surgical and adjusted EBITDA guidance, emphasized corrective actions (sales/marketing/support hires), and closed a favorable refinancing to improve the capital structure. On balance, the positive scale, profitability, and strategic momentum outweigh the execution-related headwinds noted for the quarter.View all ATEC earnings summariesATEC Stock 12 Month Forecast
Average Price Target
$18.91
▲(70.35% Upside)
Technical Analysis
Ownership Overview
39.61% Insiders
17.22% Mutual Funds
18.31% Other Institutional Investors
15.44% Public Companies and
Individual Investors